Pharma English news | Pharma, Latest News & Live Updates in English | English News (Latest English News) at Lokmattimes.com

Chennai, June 4 Pharma major Glenmark Pharmaceuticals Ltd on Friday said it has received the final approval by the US Food and Drug Administration (USFDA) for Theophylline extended release (ER) tablets, 300 mg and 450 mg.The company said the tablet is the bioequivalent and therapeutically equivalent to the Theophylline extended-release tablets, 300 mg and 450 mg, of Alembic Pharmaceuticals Limited.It is used to treat wheezing, chest tightness due to asthma, lung diseases and others for easier breathing.Glenmark has been granted a competitive generic therapy (CGT) designation for Theophylline extended-release tablets USP, 450 mg.As such, it is the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing of the 450 mg strength.According to IQVIA sales data for the 12 month period ending April 2021, the Theophylline extended release tablets, 300 mg and 450 mg market achieved annual sales of approximately $47.8 million.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

ICC Women's ODI World Cup 2025

Diwali 2025

Maharashtra News

Mumbai Local

Weather Update

Mumbai Rains

PharmaFOLLOW

Pharma, Latest News

Business :Adroit Biomed expands its immunity portfolio with launch of Glutone MD made from purest Setria Glutathione

COVID-19 treatment takes a toll on the patient's body as the medicines affect the vitals parts. ...

International :Glenmark gets USFDA approval for Theophylline ER tablets

Chennai, June 4 Pharma major Glenmark Pharmaceuticals Ltd on Friday said it has received the final approval by ... ...